Challenges and limitations in using bacterial metabolites as immunomodulators
Harnessing the immunomodulatory potential of bacterial metabolites opens up exciting possibilities for treating various immune-related disorders. However, turning this potential into a reality presents significant challenges. This review investigates these challenges, focusing on discovery, producti...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1535394/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582909591027712 |
|---|---|
| author | Chinnashanmugam Saravanan Nandana Karrath Gopinath Raja Ganesan Durairaj Thirumurugan |
| author_facet | Chinnashanmugam Saravanan Nandana Karrath Gopinath Raja Ganesan Durairaj Thirumurugan |
| author_sort | Chinnashanmugam Saravanan |
| collection | DOAJ |
| description | Harnessing the immunomodulatory potential of bacterial metabolites opens up exciting possibilities for treating various immune-related disorders. However, turning this potential into a reality presents significant challenges. This review investigates these challenges, focusing on discovery, production, characterization, stability, formulation, safety, and individual variability limitations. The limited bioavailability of many metabolites, as well as potential improvements along with the potential for off-target effects and the importance of precise targeting, are emphasized. Furthermore, the complex interactions between gut bacterial metabolites and the microbiome are investigated, highlighting the importance of personalized approaches. We conclude by discussing promising advances in metagenomics, metabolomics, synthetic biology, and targeted delivery systems, which hold out hope for overcoming these limitations and paving the way for the clinical translation of bacterial metabolites as effective immunomodulators. |
| format | Article |
| id | doaj-art-87ff2a74d9bc493096b720a225cd98c8 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-87ff2a74d9bc493096b720a225cd98c82025-01-29T06:46:04ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-01-011510.3389/fcimb.2025.15353941535394Challenges and limitations in using bacterial metabolites as immunomodulatorsChinnashanmugam Saravanan0Nandana Karrath Gopinath1Raja Ganesan2Durairaj Thirumurugan3Research & Development Division, MicroPros Lab Inc., Edmonton, AB, CanadaSchool of Biotechnology, Amrita Vishwa Vidyapeetham, Kerala, IndiaDepartment of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Chennai, Tamil Nadu, IndiaDepartment of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Chennai, Tamil Nadu, IndiaHarnessing the immunomodulatory potential of bacterial metabolites opens up exciting possibilities for treating various immune-related disorders. However, turning this potential into a reality presents significant challenges. This review investigates these challenges, focusing on discovery, production, characterization, stability, formulation, safety, and individual variability limitations. The limited bioavailability of many metabolites, as well as potential improvements along with the potential for off-target effects and the importance of precise targeting, are emphasized. Furthermore, the complex interactions between gut bacterial metabolites and the microbiome are investigated, highlighting the importance of personalized approaches. We conclude by discussing promising advances in metagenomics, metabolomics, synthetic biology, and targeted delivery systems, which hold out hope for overcoming these limitations and paving the way for the clinical translation of bacterial metabolites as effective immunomodulators.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1535394/fullgut bacterial metabolitesmicrobiomeimmunomodulatorsmetagenomicssynthetic biology |
| spellingShingle | Chinnashanmugam Saravanan Nandana Karrath Gopinath Raja Ganesan Durairaj Thirumurugan Challenges and limitations in using bacterial metabolites as immunomodulators Frontiers in Cellular and Infection Microbiology gut bacterial metabolites microbiome immunomodulators metagenomics synthetic biology |
| title | Challenges and limitations in using bacterial metabolites as immunomodulators |
| title_full | Challenges and limitations in using bacterial metabolites as immunomodulators |
| title_fullStr | Challenges and limitations in using bacterial metabolites as immunomodulators |
| title_full_unstemmed | Challenges and limitations in using bacterial metabolites as immunomodulators |
| title_short | Challenges and limitations in using bacterial metabolites as immunomodulators |
| title_sort | challenges and limitations in using bacterial metabolites as immunomodulators |
| topic | gut bacterial metabolites microbiome immunomodulators metagenomics synthetic biology |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1535394/full |
| work_keys_str_mv | AT chinnashanmugamsaravanan challengesandlimitationsinusingbacterialmetabolitesasimmunomodulators AT nandanakarrathgopinath challengesandlimitationsinusingbacterialmetabolitesasimmunomodulators AT rajaganesan challengesandlimitationsinusingbacterialmetabolitesasimmunomodulators AT durairajthirumurugan challengesandlimitationsinusingbacterialmetabolitesasimmunomodulators |